SNIPR Biome Secures €35M Series B for CRISPR Therapies

Copenhagen-based SNIPR Biome, a Danish biotech scale-up, secured €35 million in Series B funding. New investors Cystic Fibrosis Foundation and German Federal Agency for Breakthrough Innovation (SPRIN-D) participated. Existing investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners also joined the round. This capital advances SNIPR Biome's microbial CRISPR-medicine development.

The funding specifically targets CRISPR-based therapies for cystic fibrosis airway infections. It also combats antimicrobial resistance. Furthermore, the investment supports clinical trials of SNIPR001 for blood cancer patients. SNIPR Biome focuses on novel CRISPR-Cas technology, similar to work by CRISPR Therapeutics and Editas Medicine.

Advancing CRISPR-Based Antimicrobial Solutions

SNIPR Biome's technology enables precision killing of bacteria. It selectively eradicates target bacteria. This process removes antibiotic resistance genes while preserving the patient's microbial community. The company was the first to orally dose humans with a CRISPR therapeutic.

SNIPR001 is in a Phase 1b study for hematologic cancer treatment. SNIPR Biome collaborates with CARB-X and the Gates Foundation.

The new capital will develop a CRISPR-Cas therapy for Pseudomonas aeruginosa. This targets airway infections in people with cystic fibrosis. Additionally, it advances a CRISPR-based intervention to eliminate antibiotic resistance genes across various bacterial species.